Of the 36 cases of Delta-AY.1 (mountaineers) variant, 27 cases were known to have a vaccination status within the National Immunisation Management System (NIMS).
“Through routine scanning of variation in Delta a small number of sequences were detected which had acquired the spike protein mutation K417N. Information suggests that there are at least 2 separate clades of Delta with K417N. One clade is large and internationally distributed with PANGO lineage designation AY.1. A second clade found in sequences uploaded to GISAID from the USA. There is limited epidemiological information available at present.
As of 7 June 2021, 63 genomes of Delta with K417N have been identified on GISAID. from Canada (1) Germany (1), Russia (1), Nepal (2), Switzerland (4), India (6), Poland (9), Portugal (12), Japan (13), USA (14).
There are currently 36 cases of Delta-AY.1 in England (35 confirmed sequencing and 1 probable genotyping) plus an additional 10 sequences which include some cases in other UK nations and some genomes for which case data is being sought. The first 5 cases were sequenced on 26 April 2021 and were contacts of travellers to Nepal and Turkey. All these cases were detected in the West Midlands. Cases have been detected in 6 different regions in England (Table 21, Figure 26). The majority of cases are in younger individuals, with 2 cases of age 60 or over (Figure 27). Out of the 36 cases, there were 11 travel associated cases (6 travellers and 5 cases amongst contacts of travellers). Twelve cases have no history of travel or contact with travellers. Countries of travel included red-list countries (Nepal and Turkey), amber-list countries (Malaysia) and green-list countries (Singapore).
Of the 36 cases, 27 cases were known to have a vaccination status within the National Immunisation Management System (NIMS), when linked on NHS number. Of these, 18 cases occurred in people who were not vaccinated, 2 cases in people who had received their first dose within 21 days of specimen date, 5 cases in people who had received their first dose more than 21 days after specimen date. There was a total of 2 cases where there were more than 14 days between the second dose of vaccine and a positive specimen. No deaths have been recorded amongst the 36 cases.”
PHE download – SARS-CoV-2 variants of concern and variants under investigation in England – Technical briefing 15 (PDF)
The European Court of Human Rights ruled on Thursday that democratic governments can make vaccinations obligatory, in a landmark judgement rejecting complaints brought by Czech families penalised for refusing compulsory jabs for their children.
“The… measures could be regarded as being ‘necessary in a democratic society'” the court ruled, saying that the Czech health policy was consistent with the “best interests” of children.
Our opinion: ** Is there an easier or quicker way of antagonising parents in the middle of a global viral pandemic than encouraging mandatory vaccinations? We can’t think of one. Expect severe blowback **
On January 11th 2021, the vaccination Center in Lausanne, a city of 140’000 inhabitants in western Switzerland, started the COVID-19 vaccination with mRNA-based vaccines. As of February 9th, 13296 vaccine doses were administered with 12,349 patients receiving a 1st dose (10501 Pfizer/BioNTech, 1848 Moderna) and 947 receiving a 2nd dose (945 Pfizer/BioNTech, 2 Moderna). We report a case series of 9 patients with stage III hypertension documented within minutes of vaccination during the first 30 days, of which 8 were symptomatic.
Vital signs were measured with an oscillometric manometer (Omron Heathcare Europe, a HEM 907-E7) with at least 3 sets of separate values at 5-minute intervals.
Median age was 73 (IQR 22), sex distribution was 7 females for 2 males. Eight of 9 patients had a prior history of arterial hypertension with most patients on anti-hypertensive therapy. All but one patient received the Pfizer/BioNTech (BNT162b2) vaccine. Of note, the Moderna (mRNA-1273) vaccine was only introduced in late January in Switzerland. One of the patients (n°3) reported a cerebral aneurysm that was coiled within the last year, with a targeted SBP < 140mmHg. 1 Due to developing headache, the patient underwent imaging with no sign of intracranial hemorrhage. Patient n°4 did not have associated electrocardiogram changes or an increase in hs-troponins. Importantly, all patients recovered but required at most several hours of monitoring at our tertiary center’s emergency department.
We report the distribution of the Spike mutation S:T478K and its recent growth in prevalence in the SARS-CoV-2 population. While there is currently no report of association of this variant with clinical features, S:T478K’s rapid growth may indicate an increased adaption of SARS-CoV-2 variants carrying it, particularly lineage B.1.1.222.
The distribution of this mutation is higher in North America, but we could detect it also in several European countries. The location of S:T478K in the interaction complex with human ACE2 may affect the affinity with human cells and therefore influence viral infectivity.
We detected this growth starting at the beginning of 2021, and S:T478K is, at the time of writing (March 26, 2021) characterizing almost 2.0% of all sequenced SARS-CoV-2
An in silico molecular dynamics study on the protein structure of Spike has predicted that the T478K mutation, substituting a non-charged amino acid (Threonine) with a positive one (Lysine) may significantly alter the electrostatic surface of the protein, and therefore the interaction with ACE2, drugs or antibodies, and that the effect can be increased if combined by other co-occurring Spike mutations.
Another experiment showed that T478K and T478R mutants were enriched when SARS-CoV-2 viral cultures were tested against weak neutralizing antibodies, highlighting, at least in vitro, a possible genetic route the virus can follow to escape immune recognition. Everything considered, we believe that the continued genetical and clinical monitoring of S:T478K and other Spike mutations is of paramount importance to better understand COVID-19 and be able to better counteract its future developments.
“Wheezing, chest or stomach pain, swelling or coldness in an arm or leg, severe headache or worsening or blurred vision after vaccination, persistent bleeding, small multiple bruises, reddish or purplish spots or blisters of blood under the skin” – if you have these symptoms after vaccination against Covid with AstraZeneca serum seek medical help immediately and report that you have recently been vaccinated.
European Medicines Agency (EMA), the corona vaccine from the manufacturer Astra-Zeneca can cause severe allergic reactions. Anaphylaxis and hypersensitivity reactions should be included in the list of possible side effects of the vaccine citing , the EMA said on Friday, several such cases in the UK.
SAGE scientists have urged Boris Johnson, the UK’s prime minister, to keep secondary schools closed in January because of concerns about a new, more virulent strain of coronavirus.
The Scientific Advisory Group for Emergencies said that the R rate — at which the virus reproduces — could be kept below the crucial 1 level if schools remained shut. Sage also warned that another national lockdown could be necessary at a meeting last week, according to the Politico website
There have now been more than 60,000,000 confirmed coronavirus infections globally and the infection rate is still increasing.
Seven countries are now reporting mink-related Sars-CoV-2 mutations in humans, according to new scientific analysis.
The mutations are identified as Covid-19 mink variants as they have repeatedly been found in mink and now in humans as well.
Uncertainty around the implications of the discovery of a Covid-19 mink variant in humans led Denmark, the world’s largest mink fur producer, to launch a nationwide cull earlier this month.
The cull was sparked by research from Denmark’s public health body, the Statens Serum Institut (SSI), which showed that a mink variant called C5 was harder for antibodies to neutralise and posed a potential threat to vaccine efficacy.
Denmark, the Netherlands, South Africa, Switzerland, the Faroe Islands, Russia and the US have all reported cases of mink-related mutations.
Only part of the European Union population can be inoculated against the new coronavirus before 2022, EU officials said in an internal meeting, as the vaccines the bloc is securing may not prove effective or may not be manufactured in sufficient doses
Mask-wearing will be obligatory for adults and older pupils in schools starting Wednesday in several more cantons, in reaction to the second wave of coronavirus cases. The University of Bern has already moved to expand distance-learning
Swiss government: “The second wave has arrived”
The second wave of Covid-19 has arrived in Switzerland faster and stronger than expected. Just over 3,000 new positive coronavirus cases and eight deaths were reported on Tuesday. The seven-day average of new cases has increased by 123% on the previous week to 2,636.